Open Orphan PLC New challenge study quarantine clinic (7839N)
February 03 2021 - 2:00AM
UK Regulatory
TIDMORPH
RNS Number : 7839N
Open Orphan PLC
03 February 2021
Open Orphan plc
("Open Orphan" or the "Company")
New challenge study quarantine clinic
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
pharmaceutical services contract research organization (CRO) and
world leader in vaccine and antiviral testing using human challenge
clinical trials, announces that hVIVO, part of Open Orphan plc, has
opened a new quarantine clinic in East London. The new site is
based in Whitechapel, directly opposite the Queen Mary
BioEnterprise Innovation Centre ("QMB") which houses hVIVO's 24
bedroom unique state-of-the-art FluCamp site and the recently
opened new street-level volunteer screening centre. The Whitechapel
Clinic will act as an extension of hVIVO`s current QMB site.
The converted 26-bedroom former boutique hotel, which will be
known as the Whitechapel Clinic, has the capacity for up to 19
quarantine rooms and will be used as an additional unit for human
challenge trials and volunteer recruitment screening. The
quarantine rooms are located across three floors of the former
hotel, with each level fully converted to include a nurses station
on each floor.
The new site, like QMB, will follow the highest safety standards
to deliver each clinical study and volunteer screening visit. Of
the 19 rooms, 8 rooms on a single floor are flexible use clinic
rooms, meaning they can be used as either quarantine bedrooms for
challenge studies or for volunteer screening visits. Each room at
the facility has been fully repurposed to the highest standard,
with all volunteer rooms equipped with an en-suite bathroom, TV,
wardrobe, and tea & coffee making facilities. This will provide
a comfortable space for volunteers during studies. The Whitechapel
Clinic, like QMB, is also equipped with a 24-hour security presence
and a working hour reception desk.
Cathal Friel, Exexcutive Chairman of Open Orphan plc commented:
"Our newest quarantine unit greatly increases our capacity to
facilitate hVIVO's pipeline of upcoming studies. Our QMB clinic is
now close to full capacity until December 2021, and as such, the
newly renovated, state of the art Whitechapel Clinic will allow us
to increase our study capacity substantially in the year ahead.
"We have leased the entire former Whitechapel Hotel and managed
to convert the space on a very cost efficient basis which is now
almost fully booked to capacity for H1 2021. This new facility will
be run at the same high standard as our QMB site, and volunteers
will be expertly supervised by our highly trained nurses and
doctors in a safe and controlled clinical environment."
Interested in becoming a volunteer?
If you are interested in being contacted and provided with
details about future COVID-19 human challenge study research,
please leave your contact details at www.UKCovidChallenge.com .
hVIVO recruits many of its volunteers for its challenge study
clinical trials through its dedicated volunteer recruitment
website, www.flucamp.com . By volunteering to take part in one of
our studies in a safe, controlled, clinical environment under
expertly supervised conditions you are playing your part to further
medical research and help increase the understanding of respiratory
illnesses.
For further information please contact:
Open Orphan plc +353 (0) 1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser
and Joint Broker) +44 (0) 20 7614 5900
John Llewellyn-Lloyd / Benjamin Cryer
/ Dan Gee-Summons
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson/ Richard
Chambers
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & +44 (0)20 7933 8780 or openorphan@walbrookpr.com
IR)
+44 (0)7876 741 001 / +44
Anna Dunphy / Paul McManus (0)7980 541 893
About Open Orphan ( www.openorphan.com )
Open Orphan is a rapidly growing niche CRO pharmaceutical
services company which is a world leader in the testing of vaccines
and antivirals through the use of human challenge clinical trials.
Conducted from Europe's only 24-bedroom quarantine clinic with
onsite virology providing individually isolated rooms and connected
to our specialist laboratory facility. hVIVO's challenge studies
require healthy volunteers to take part, volunteers are recruited
through FluCamp, learn more at www.FluCamp.com . The hVIVO facility
offers highly specialised virology and immunology laboratory
services to support pre-clinical and clinical respiratory drug,
antiviral, and vaccine discovery and development. Reliable
laboratory analysis underpinned by scientific expertise is
essential when processing and analysing clinical samples. Robust
quality processes support our team of scientists in the delivery of
submission ready data.
The Company has a leading portfolio of 8 viral challenge study
models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD
viral challenge models. As announced in early March, Open Orphan is
rapidly advancing a number of Coronavirus challenge study models
and expects to be helping many COVID-19 vaccine development
companies to test their vaccines. No other company in the world has
such a portfolio, with only two competitors globally having 1
challenge study model each. hVIVO also works with companies in the
UK and Ireland to provide COVID-19 testing to staff to protect
staff and customers from a workplace COVID-19 outbreak through its
COVID Clear offering.
Open Orphan comprises of two commercial specialist CRO services
businesses, hVIVO and Venn Life Sciences and is also building out a
valuable data platform business. hVIVO has built up one of the
world's largest databases of infectious disease progression data
and we are populating our Open Orphan Health Data platform with
this historical hVIVO data. In our clinical trials going forward,
we are also planning to collect data on volunteers via wearables
during clinical trials. Therefore, Open Orphan's data, which may
yield valuable digital biomarkers, could be one of the more
sought-after datasets by many of the large wearables /smart watch
wearables providers around the world. In June 2019, Open Orphan
acquired AIM-listed Venn Life Sciences Holdings plc in a reverse
take-over and in January 2020 it completed the merger with hVIVO
plc. Venn is an integrated drug development consultancy firm which
offers CMC (chemistry, manufacturing and controls), preclinical,
Phase I & II clinical trials design and execution. The merger
with hVIVO created a European full pharma services company
broadening the Company's customer base and with complementary
specialist CRO services, widened the range of the Company's service
offerings.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDKBBDCBKDNBK
(END) Dow Jones Newswires
February 03, 2021 02:00 ET (07:00 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jul 2023 to Jul 2024